Navigation Links
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Date:12/19/2007

Avastin offers patients the chance to live twice as long without their

disease advancing

BASEL, Switzerland, Dec. 19 /PRNewswire/ -- Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced renal cell cancer (RCC) in combination with interferon (IFN), the current standard of care*. Kidney cancer, known as renal cell carcinoma (RCC) is a disease that kills over 100,000 people per year world-wide(1).

There are few early symptoms in kidney cancer which means that unfortunately the majority of patients are diagnosed with advanced disease, where current treatment options are limited. Kidney cancer is highly resistant to chemotherapy and radiotherapy, which are often key weapons against other cancer types(2).

The approval was based on data from the pivotal phase III AVOREN trial, which showed that patients with advanced RCC who received Avastin in combination with IFN lived nearly twice as long without their disease progressing ("progression free survival"), as those who received IFN alone.

"The results of the AVOREN study confirmed that Avastin is a safe, effective and well tolerated treatment option for patients with advanced renal cell cancer," said Professor Bernard Escudier, Head of the Immunotherapy and Innovative Therapy Unit, Institut Gustave-Roussy, Paris, France and Principal Investigator of the pivotal AVOREN study. "Avastin effectively doubles the time in which patients live without their disease getting worse, so this approval has the potential to change the treatment landscape for this disease, where treatment options are still limited."

Avastin Approval Status

Kidney cancer is the fourth cancer type in which Avastin has demonstrated positive survival benefits for patients. Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in advanced colorectal
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Medpace Strengthens Presence in Central Europe
9. Kline Study: Better Brushing Habits Boost European Oral Care Sales
10. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
11. European Centre for Modern Drug Discovery Established in Hamburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
(Date:7/24/2014)... Yan, Distinguished Professor of Engineering at the University ... to solve problems in energy engineering, environmental sustainability ... on zeolites, porous rock with a well-defined, crystalline ... is so precisely decided that zeolites can separate ... of an angstrom (one-tenth of a nanometer), making ...
(Date:7/24/2014)... , July 24, 2014 SRI International has ... the National Institute of Allergy and Infectious Diseases (NIAID), ... preclinical development of potential therapies for HIV infection and ... treat HIV and AIDS and the complications and opportunistic ... for preventing sexual transmission of HIV. ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... BUFFALO, N.Y., April 19, 2011 Today, H. ... CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused ... Kinase (FAK) inhibitors for cancer, provided a company ... leaders at the Celebration of Innovation Showcase 2011 ...
... April 19, 2011 Practice Fusion, the leading EHR ... the addition of Paul Willard as Vice President of ... Development. The news of the expanded executive team follows ... the Electronic Health Record system , led by ...
... Tissue Genesis, Inc., an emerging leader in adult ... has begun clinical trials for peripheral vascular disease (PVD) ... at the University of Louisville Hospital.  Tissue Genesis is ... patient,s own adipose-derived adult stem cells (ASCs) prepared at ...
Cached Biology Technology:CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 3CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 4Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director 2Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director 3Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director 4Tissue Genesis Begins FDA-Approved Clinical Trial 2Tissue Genesis Begins FDA-Approved Clinical Trial 3
(Date:7/25/2014)... PITTSBURGH -- The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... the UPMC/UPCI Multidisciplinary Thyroid Center and other diagnostic ... the correct initial surgery by 30 percent, according ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Acoustic disturbance has different effects on different species ... the Universities of Bristol and Exeter which tested ... sooner to a flying seagull predator model when ... observed in European minnows. , Lead author ... Sciences said: "Noise levels in many aquatic environments ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... , A group of Japanese researchers, who publish their findings ... Biomimetics , have succeeded in building a fully functional replica ... they have filmed their model butterfly flying. Among the ... wing area is very large relative to their body mass. ...
... to minimize the use of chemical herbicides need creative solutions ... research at the University of Illinois on Canada thistle, Sudangrass ... smother crop. "Sudangrass get very tall. It outcompetes the ... occur in the thistle," said U of I weed scientist ...
... NC Social status in paper wasps is established earlier ... month in the journal PLoS ONE . While ... appearance and are fixed from birth, paper wasp society is ... can climb the social ladder and become a queen. Now, ...
Cached Biology News:Sudangrass recommended to combat Canada thistle 2Sudangrass recommended to combat Canada thistle 3The making of a queen: Road to royalty begins early in paper wasps 2
... Lab Quantas unique combination of Coulter ... resolution capabilities and accurate cell counting. ... wavelengths, including UV, allowing flexible fluorochrome ... applications typically only achievable with larger, ...
... FC 500 Series is a ... the most advanced technologies available. ... flexible testing, powerful software and ... help researchers optimize their overall ...
... crosslinked to protein G-agarose beads which can ... heart mitochondria. Also included are 2 mg ... ,The pyruvate dehydrogenase complex (PDH) immunocapture kit ... of tissue. This facilitates the subsequent analysis ...
... PULSin may be superior to transfection in ... transfection, with PULSin you can study lethal ... course of proteins in cells. Likewise, delivery ... than traditional RNA interference experiments. ,With ...
Biology Products: